DANBURY, Conn. Danbury-based specialty biopharmaceutical company Biodel has been awarded a two-year grant by the National Institute of Health (NIH) to develop therapies for use in an artificial pancreas.
The $582,763 grant is part of the NIHs Small Business Innovation Research (SBIR) program, and the money will be used to develop stable glucagon formulations for use in an artificial pancreas, which Biodel said is known as a closed-loop pump system.
Biodel specializes in commercial treatments for diabetes, and the companys work is supported by the NIHs National Institute of Diabetes and Digestive and Kidney Diseases.
Biodel has a great deal of expertise in developing stable glucagon formulations for the treatment of severe hypoglycemia and our lead program is targeting an NDA [New Drug Application] submission in early 2014, Dr. Errol De Souza, the companys president and CEO, said in a statement.
We will leverage this expertise and concentrate the resources funded by the SBIR on utilizing our proprietary technology to produce glucagon formulations that support the development of effective artificial pancreas therapy, De Souza added.
Click here to follow Daily Voice Danbury and receive free news updates.